Several reports showed the involvement of stimulation of IR by insulin or IGF-2 in cancer cell progression [51, 52] suggesting that IGF-1R and IR both are therapeutic targets and inhibition of both receptors may be required for optimal tumor growth inhibition. The gene discussed is IGF1R; the disease is neoplasm.